glp-1 no bmi requirement and Weight Loss Treatment: What BMI Qualifies? These are the 2027 REQUIREMENTS

This initiative has the potential to make a lasting impact in our communities by providing more reliable, consistent access to these life-changing medications for the millions of Americans who want a better, more affordable way to take care of their health. According to the World Health Organization (WHO), around 70% of American adults have obesity or are overweight and at least 2.8 million people die each year due to being overweight or having obesity

K., Lam, S

Data from clinical trials with semaglutide use in pregnant patients are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

Some of the most well-known include: Ozempic (semaglutide) Wegovy (semaglutide) Mounjaro (tirzepatide) Zepbound (tirzepatide) These medications have undergone extensive clinical testing for safety, effectiveness, dosing, and manufacturing consistency

TL;DR - What You Need to Know About FeelGood GLP-1 in 60 Seconds FeelGood GLP-1 is a telehealth platform connecting patients with licensed medical providers for evaluation and, when clinically appropriate, access to compounded GLP-1 injections starting at $149 per month - in a category where FDA formally proposed in April 2026 removing semaglutide and tirzepatide from the 503B outsourcing bulks list - with a public comment period open through June 2026